A User-Friendly System for Mailed Dosimetric Audits of (192)Ir or (60)Co HDR Brachytherapy Sources.

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Oliver-Canamas, Laura
- Candela-Juan, Cristian
- Pujades-Claumarchirant MC
- Rovira-Escutia, Juan J.
Grupos
Abstract
OBJECTIVES: The main goal of this work is to design and characterize a user-friendly methodology to perform mailed dosimetric audits in high dose rate (HDR) brachytherapy for systems using either Iridium-192 ((192)Ir) or Cobalt-60 ((60)Co) sources. METHODS: A solid phantom was designed and manufactured with four catheters and a central slot to place one dosimeter. Irradiations with an Elekta MicroSelectron V2 for (192)Ir, and with a BEBIG Multisource for (60)Co were performed for its characterization. For the dose measurements, nanoDots, a type of optically stimulated luminescent dosimeters (OSLDs), were characterized. Monte Carlo (MC) simulations were performed to evaluate the scatter conditions of the irradiation set-up and to study differences in the photon spectra of different (192)Ir sources (Microselectron V2, Flexisource, BEBIG Ir2.A85-2 and Varisource VS2000) reaching the dosimeter in the irradiation set-up. RESULTS: MC simulations indicate that the surface material on which the phantom is supported during the irradiations does not affect the absorbed dose in the nanoDot. Generally, differences below 5% were found in the photon spectra reaching the detector when comparing the Microselectron V2, the Flexisource and the BEBIG models. However, differences up to 20% are observed between the V2 and the Varisource VS2000 models. The calibration coefficients and the uncertainty in the dose measurement were evaluated. CONCLUSIONS: The system described here is able to perform dosimetric audits in HDR brachytherapy for systems using either (192)Ir or (60)Co sources. No significant differences are observed between the photon spectra reaching the detector for the MicroSelectron V2, the Flexisource and the BEBIG (192)Ir sources. For the Varisource VS2000, a higher uncertainty is considered in the dose measurement to allow for the nanoDot response.
Datos de la publicación
- ISSN/ISSNe:
- 2072-6694, 2072-6694
- Tipo:
- Article
- Páginas:
- -
- Factor de Impacto:
- 1,349 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Cancers MDPI
Documentos
- No hay documentos
Métricas
Filiaciones
Keywords
- dosimetric audit; error detection; high dose rate brachytherapy; phantom
Campos de estudio
Proyectos asociados
ESTUDIO EN FASE III, ALEATORIZADO, CON DOBLE ENMASCARAMIENTO Y CONTROLADO CON PLACEBO, DE NIVOLUMAB O NIVOLUMAB CON CISPLATINO, EN COMBINACIÓN CON RADIOTERAPIA EN PARTICIPANTES CON CARCINOMA DE CÉLULAS ESCAMOSAS DE CABEZA Y CUELLO (CCECC) LOCALMENTE AV A NZADO ELEGIBLES O NO PARA RECIBIR TRATAMIENTO CON CISPLATINO.
Investigador Principal: MIGUEL PASTOR BORGOÑON
CA209-9TM . 2018
CHAIMELEON. ACCELERATING THE LAB TO MARKET TRANSITION OF AI TOOLS FOR CANCER MANAGEMENT.
Investigador Principal: LUIS MARTÍ BONMATÍ
952172 . COMISION EUROPEA . 2020
ESTUDIO DE FASE 3 DE PEMBROLIZUMAB (MK-3475) EN COMBINACIÓN CON QUIMIORRADIOTERAPIA CONCURRENTE, SEGUIDOS DE PEMBROLIZUMAB CON O SIN OLAPARIB, FRENTE A QUIMIORRADIOTERAPIA CONCURRENTE SEGUIDA DE DURVALUMAB EN PARTICIPANTES CON CÁNCER DE PULMÓN NO MICROCÍTICO (CPNM) EN ESTADIO III, LOCALMENTE AVANZADO E IRRESECABLE.
Investigador Principal: ÓSCAR JOSÉ JUAN VIDAL
MK-7339-012 . 2020
ESTUDIO DE BRAQUITERAPIA ELECTRÓNICA PARA CARCINOMA CUTÁNEO BASOCELULAR.
Investigador Principal: JOSÉ PÉREZ CALATAYUD
BCCBRACHY
UTILIZACIÓN DE LA RADIOTERAPIA INTRAOPERATORIA EN LA NEOPLASIA DE MAMA.
Investigador Principal: FRANCISCO JAVIER CELADA ÁLVAREZ
SESPM-19-1 . 2021
Cita
Oliver L,Vijande J,Candela C,Gimeno J,Pujades MC,Rovira JJ,Ballester F,Perez J. A User-Friendly System for Mailed Dosimetric Audits of (192)Ir or (60)Co HDR Brachytherapy Sources. Cancers (Basel). 2023. 15. (9):2484. IF:4,500. (1).